News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
682,081 Results
Type
Article (38928)
Company Profile (275)
Press Release (642878)
Section
Business (203791)
Career Advice (1983)
Deals (35354)
Drug Delivery (83)
Drug Development (80755)
Employer Resources (168)
FDA (16079)
Job Trends (14792)
News (344392)
Policy (32427)
Tag
Academia (2530)
Alliances (49021)
Alzheimer's disease (1185)
Approvals (15997)
Artificial intelligence (109)
Bankruptcy (352)
Best Places to Work (11420)
Biotechnology (195)
Breast cancer (92)
Cancer (809)
Career advice (1653)
Cell therapy (184)
Clinical research (63735)
Collaboration (279)
Compensation (154)
COVID-19 (2514)
Cystic fibrosis (78)
Data (711)
Diabetes (120)
Diagnostics (6065)
Drug pricing (73)
Earnings (83883)
Employer resources (145)
Events (108521)
Executive appointments (225)
FDA (16470)
Funding (255)
Gene therapy (136)
GLP-1 (547)
Government (4313)
Healthcare (18644)
Infectious disease (2579)
Inflammatory bowel disease (98)
Interviews (306)
IPO (16245)
Job creations (3622)
Job search strategy (1414)
Layoffs (405)
Legal (7847)
Lung cancer (142)
Manufacturing (139)
Medical device (13115)
Medtech (13120)
Mergers & acquisitions (19085)
Metabolic disorders (333)
Neuroscience (1410)
NextGen Class of 2024 (6486)
Non-profit (4461)
Northern California (1086)
Obesity (201)
Opinion (175)
Patents (89)
People (56061)
Phase I (19754)
Phase II (28059)
Phase III (20968)
Pipeline (184)
Postmarket research (2553)
Preclinical (8403)
Radiopharmaceuticals (234)
Rare diseases (171)
Real estate (5887)
Regulatory (21399)
Research institute (2306)
Resumes & cover letters (348)
Southern California (1004)
Startups (3560)
United States (10720)
Vaccines (520)
Weight loss (151)
Date
Today (156)
Last 7 days (581)
Last 30 days (2660)
Last 365 days (36085)
2024 (29185)
2023 (40074)
2022 (51173)
2021 (55712)
2020 (54087)
2019 (46541)
2018 (35019)
2017 (32111)
2016 (31480)
2015 (37553)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (713)
Arizona (183)
Asia (36949)
Australia (6023)
California (2475)
Canada (1122)
China (190)
Colorado (107)
Connecticut (106)
Europe (79072)
Florida (354)
Georgia (88)
Illinois (293)
Indiana (167)
Kansas (95)
Maryland (480)
Massachusetts (2004)
Michigan (140)
Minnesota (241)
New Jersey (743)
New York (761)
North Carolina (639)
Northern California (1086)
Ohio (120)
Pennsylvania (712)
South America (1091)
Southern California (1004)
Texas (340)
Utah (71)
Washington State (292)
682,081 Results for "duchesnay inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Duchesnay Pharmaceutical Group celebrates expansion of its treatment portfolio for nausea and vomiting of pregnancy to 40 countries around the world
October 10, 2024
·
3 min read
Duchesnay Inc. is seeking Health Canada approval for a segesterone acetate/ethinyl estradiol contraceptive vaginal system, a new option for women
Duchesnay Inc., member of Duchesnay Pharmaceutical Group (DPG) one of the few anchor companies selected by the Government of Canada for its Global Hypergrowth Project, has recently filed a New Drug Submission (NDS) to Health Canada for its segesterone acetate / ethinyl estradiol slow-release vaginal system developed for contraception control.
November 30, 2023
·
5 min read
Duchesnay announces the launch of Vablys® (dequalinium chloride vaginal tablets), an antiseptic and anti-infective treatment for bacterial vaginosis
Duchesnay Inc, a pharmaceutical company specializing in women’s health and part of Duchesnay Pharmaceutical Group headquartered in Blainville, Quebec, is pleased to announce that it has launched its newest treatment, Vablys ® (dequalinium chloride vaginal tablets).
June 21, 2022
·
4 min read
Slynd® (drospirenone), a new progestin-only contraceptive pill from Duchesnay which offers a 24-hour safe window for a missed pill
A new progestin-only contraceptive pill is now available to Canadians from Duchesnay Inc., a pharmaceutical company specializing in women’s health and part of the Duchesnay Pharmaceutical Group headquartered in Blainville, Quebec.
May 17, 2022
·
4 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
Press Releases
Verrica Pharmaceuticals Announces Litigation Settlement with Dormer Laboratories, Inc.
Verrica Pharmaceuticals Inc. today announced the settlement of litigation with Dormer Laboratories, Inc. (“Dormer Labs”).
July 1, 2024
·
5 min read
Postmenopausal Canadian women experiencing vaginal dryness and painful intercourse have a new oral once-daily prescription treatment, Osphena® (ospemifene tablets) from Duchesnay
Duchesnay Inc., a pharmaceutical company specializing in women’s health and part of the Duchesnay Pharmaceutical Group based in Blainville, Quebec, is proud to announce the first treatment launched by its new ownership and management team to help postmenopausal women across Canada who are suffering from vaginal dryness and painful intercourse.
February 14, 2022
·
7 min read
Press Releases
Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. Announce Business Combination to Form Dogwood Therapeutics, Inc. (Nasdaq: “DWTX”)
October 8, 2024
·
14 min read
Lophos Holdings Inc. Announces the Completion of Securities Purchase Agreement with ThreeD Capital Inc.
Lophos Holdings Inc. (CSE: MESC) (“Lophos” or the “Company”), a Canadian bioscience company focused on the cultivation and sale of Lophophora williamsii (“Peyote”) and ThreeD Capital Inc. (CSE: IDK) (OTCQB: IDKFF) (“ThreeD”), a Canadian-based venture capital firm focused on opportunistic investments in companies in the junior resources and disruptive technologies sectors, are pleased to announce the completion of its previously announced Securities Purchase Agreement (the “Agreement”).
June 20, 2024
·
4 min read
Press Releases
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) and HOPE Therapeutics, Inc. Announce Participation at the ThinkEquity Conference October 30, 2024
October 24, 2024
·
4 min read
1 of 68,209
Next